Abstract

Pancreatic cancer (PC) is highly malignant and lacks an effective therapeutic schedule, hence that early diagnosis is of great importance to achieve a good prognosis. Oral bacteria have been proved to be associated with pancreatic cancer, but the specific mechanism has not been comprehensively illustrated. In our study, thirty-seven saliva samples in total were collected with ten from PC patients, seventeen from benign pancreatic disease (BPD) patients, and ten from healthy controls (HC). The oral bacterial community of HC, PC, and BPD groups was profiled by 16S rDNA high-throughput sequencing and bioinformatic methods. As shown by Simpson, Inverse Simpson, Shannon and Heip, oral microbiome diversity of HC, BPD and PC groups is in increasing order with the BPD and PC groups significantly higher than the HC group. Principal coordinate analysis (PCoA) suggested that grouping by PC, BPD and HC was statistically significant. The linear discriminant analysis effect size (LEfSe) identified high concentrations of Fusobacterium periodonticum and low concentrations of Neisseria mucosa as specific risk factors for PC. Furthermore, predicted functions showed changes such as RNA processing and modification as well as the pathway of NOD-like receptor signaling occurred in both PC and HC groups. Conclusively, our findings have confirmed the destruction of oral bacterial community balance among patients with PC and BPD and indicated the potential of Fusobacterium periodonticum and Neisseria mucosa as diagnostic biomarkers of PC.

Highlights

  • Pancreatic cancer (PC) is a common malignant tumor, leading to around 432,242 deaths worldwide in 2018 [1]

  • After applying rigorous inclusion and exclusion criteria, a total of ten PC patients, seventeen benign pancreatic disease (BPD) patients and ten healthy controls (HC) subjects were involved in this study

  • The HC group has a lower average age, it is still appropriate for this study as the control considering the temporal stability of the oral microbiome

Read more

Summary

Introduction

Pancreatic cancer (PC) is a common malignant tumor, leading to around 432,242 deaths worldwide in 2018 [1]. Patients in the early stage of PC have few symptoms, and the disease is commonly diagnosed during intermediate and advanced stages for which there is no effective clinical treatment [2]. The fiveyear relative survival rate of PC patients was around 9% [3]. Looking for new potential biomarkers will benefit PC patient’s early diagnosis greatly. CA19.9 (carbohydrate antigen 19.9) was released into blood by PC cells and widely used in clinical diagnosis [4, 5]. The testing result based on CA19.9, as well as other serological markers such as CEA (carcinoembryonic antigen) are not so reliable [6,7,8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call